Home  |  About JAPTR |  Editorial board  |  Search |  Ahead of print  |  Current issue  |  Archives |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |Login 
Users Online: 1078   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
     

 Table of Contents  
ORIGINAL ARTICLE
Year : 2016  |  Volume : 7  |  Issue : 1  |  Page : 17-21  

Application of critical path analysis in clinical trials


1 Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
2 Clinical Research Organization, R and D Core Committee, Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India

Date of Web Publication6-Jan-2016

Correspondence Address:
Bhaswat S Chakraborty
R and D Core Committee, Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2231-4040.173263

Rights and Permissions
  Abstract 

Clinical research operates in a strictly regulated environment under various management models, but a distinct management model of clinical trial (CT) still needs exploration and research. Critical path analysis (CPA) is a management approach can be used for monitoring, analysis, and prediction of success of its time-bound operational activities. A model CT was compiled with 78 activities, which were further merged into 35 major activities. After performing dependence analysis, the list was finalized with 25 activities which were taken in activity predecessor to create a network diagram and perform CPA considering patients, conduct, and outcome. Activities were inclusive, described the trial entirely with accuracy, and were in chronological and logical sequences. This approach does not replace an understanding of or adherence to the requirements contained in all applicable regulations, guidelines or standard operating procedures governing clinical studies but ensures the proper use of operational and decisional approaches including optimal resource management. As the need to meet deadlines becomes more important and the need to produce good, stable project plans, CPA is very useful for determining activities that can lead to project delay. With this approach, project may be effectively monitored, and realistic schedules can be maintained.

Keywords: Clinical trial operation, critical path analysis in clinical trial, decision model in clinical trial


How to cite this article:
Kumar A, Chakraborty BS. Application of critical path analysis in clinical trials. J Adv Pharm Technol Res 2016;7:17-21

How to cite this URL:
Kumar A, Chakraborty BS. Application of critical path analysis in clinical trials. J Adv Pharm Technol Res [serial online] 2016 [cited 2021 Sep 16];7:17-21. Available from: https://www.japtr.org/text.asp?2016/7/1/17/173263


  Introduction Top


Within clinical trials (CTs) there are three dimensions where activities, their duration, and the conditions on which these time-bound activities unfold decide the fate of the study. These are: (1) Assessment of safety – prediction if a potential medicinal product will have any safety concerns through the evaluation of its potential adverse effects, (2) proof of concept and large studies efficacy, (3) postmarketing surveillance, pharmacovigilance, and periodic safety update reports. The coordination of an individual CT project and the general management of the projects running simultaneously have a strategic importance to ensure timely marketing authorization of the promising candidates in the portfolio.[1],[2],[3] In all phases of CTs, the common management items tend to remain the same, i.e., the scope, resources, and the timelines.[4],[5],[6] The productivity of the pharmaceutical industry has decreased over time, and the costs of producing new medicines have been rising sharply.[7],[8] Critical path analysis (CPA) is a method which is intended to improve drug development and reduce uncertainty and cost by applying scientific tools to the clinical development process.

When activity durations are deterministically or experientially known, the CPA can be applied to manage time and resources for a given trial.[9],[10] The motivation for CPA and overall project management for CTs come from the fact that there are many dependent and independent (parallel) activities involved, and also there are many uncertainties. To meet the objective of systematic planning, the managements have evolved a number of techniques applying network strategy. CPA is one of the many network techniques which have been widely used for planning, scheduling and controlling the large and complex projects. CPA formally identifies tasks which must be completed on time for the timely completion of the whole project. It also identifies which tasks can be delayed if the resource needs to be reallocated to catch up on missed or overrunning tasks. A further benefit of CPA is that it helps us to identify the minimum length of time needed to complete a project. Where we need to run an accelerated project, it helps us to identify which project steps we should accelerate to complete the project within the available time. The disadvantage of CPA, if we use it as the technique by which our project plans are communicated and managed against, is that the relation of tasks to time is not as immediately obvious as with Gantt charts. This can make them more difficult to understand.[11],[12]

CPA emphasizes on activities and not on uncertainties while estimating its activity times.[13],[14],[15] It is not always possible to sort out completely identifiable activities and their start and finish times. Time estimates have an element of subjectiveness in them. In this paper, we tried to design and develop an innovative CT management approach for a project-specific operating plan during the conduct of the study. This CT management approach does not replace an understanding of or adherence to the requirements contained in all applicable regulations, guidelines, or standard operating procedures governing these studies but ensures optimization of CT design, analysis, trial management, and cost.


  Rational Methodology, Approach, and Results Top


Initially, the activity list of a model CT was listed in different 78 activities, which was further merged into the major 35 activities. After further consideration and dependence analysis, it was finalized in the 25 activities which were taken in activity predecessor table for the purpose of network diagram and CPA considering patients, conduct and outcome [Table 1]. Activities are inclusive; describe the trial entirely with accuracy, in chronological and logical sequences. Dependency nature is both qualitative and quantitative [Table 2] and also validated by experts. Primary and secondary outcomes were appropriate, ethically approved, approved by the concerned regulatory agency, scientifically standardized as well as patients were well cared [Figure 1].
Table 1: These 25 activities were taken to create a network diagram and perform CPA considering patients, conduct, and outcome

Click here to view
Table 2: Activity - predecessor relationship to describe how each activity is dependent or independent from another activity which precedes this given activity

Click here to view
Figure 1: Network diagram based on the activity-predecessor table including activities from start to finish. In this figure, all 25 activities mentioned in [Table 1] and [Figure 2] were taken to design the network A–Y. The activities which were linked to another activity (ies) are connected with the direct line to show inter-dependent relationships

Click here to view


To determine the flow of these activities, we need to create a precedence diagram. Activities which must be completed before a particular activity starts are called predecessor activities, and those which must follow a particular activity are called successor activities. After deciding the precedence order, the activities are put in a logical sequence using the graphical notations. While constructing the network, to ensure that the activities fall in a logical sequence, the following questions need to be answered: (1) What activities must be completed before a particular activity starts? (2) What activities follow this? (3) What activities must be performed concurrently with this?

Critical path analysis

A delay in any of the critical path activities will delay the entire project, regardless of whether the other project activities are completed on or before time. The act of determining the critical path is known as the CPA.[14],[16] The precedence diagram shown in [Figure 2] has multiple paths highlighted as the green line, red line. One of the paths in [Figure 2] is the critical path.
Figure 2: The red line of this diagram describes the critical path of the activities from the starting point to completion of a clinical trial. Please refer to [Table 2] for the activities named A–Y

Click here to view


Slack and float both refer to the amount of time by which a particular event or activity can be delayed without affecting the time schedule of the network. The total float of an activity is the difference of its latest start time and its earliest start time. The activities which have zero floats are critical activities and are on the path of critical activities, the critical path. Total float represents the time by which an activity can be delayed without affecting the project completion time.[17]

In this network diagram, critical activities such as development of protocol and investigator brochure, informed consent form translations, review, approval, translation certificate, study insurance certificate, site initiation visit (SIV) preparation, dispatch of investigational product and other site requirements, SIV, data entry, data validation, data clarification form generation and tracking, reconcile final records, and close study plays vital role. Some of the noncritical activities of this project include development of drug supply management plan, Clinical Trial Registry of India registration, preparation of ethics committee submission packets, and allocation of sites to the Clinical Research Associate [Figure 3].
Figure 3: The diagram shown above describes the multiple paths highlighted with different colors with multiple activities and longest path that is, red lined path is the critical path of the project

Click here to view


The longest path without any slack is the critical path. From the above diagram, we can see that path red lined is the longest as compared to green and blue lined path. Therefore, if activity on this path is delayed, then the project will be delayed. After identifying the critical path, we can deduce the activities that when delayed will not impact the project. Calculating the float of each activity using the CPA to determine the amount of time an activity may be late without delaying the project. The proof of concept application of CPA and related technique was corroborated.


  Discussion Top


By executing this approach repeatedly, an arbitrarily large number of realizations of project completion time may be generated allowing inference of its uncertainty. In addition, cost uncertainty with time-dependent effects can also be quantified by secondary calculations in the project network.[18] Some believe that a project plan is just a list of specific tasks and deliverables, organized across time and into larger groupings that begin and end with major project milestones.[19],[20] However, a project plan is not just a timeline management but also achieving the objectives clearly and being answerable to stakeholders by managing well all sorts of resources.

Major factors in determining the success or failure of clinical development projects are how well the planning process is carried out, whether the clinical project managers are involved early enough to understand the product development goals, executive sponsorship, and stakeholder involvement. Senior level leadership in the planning phase is common in established pharmaceutical companies, but we recommend that the attention is given to developing strategic development plans also extend to individual clinical study plans. In smaller biopharmaceutical companies without dedicated project management offices, strategic product development planning conducted to satisfy investors usually lacks a rigorous operational component. In the absence of mid to senior management leadership, this planning is almost nonexistent, increasing the risks for each individual clinical study.[18],[21] In the clinical research setting, a project is a unique CT. It has a discrete start date and end date. The project team works within a matrix reporting environment to ensure that the tasks required for completing the project are done within the project timeline and with the quality that meets or exceeds the client's expectations.[22] Within a Clinical Research Organization, project management can include satisfying the client, supporting the project team, and senior management. This is not an easy process. Most of the time, the project manager ends up sitting on a fence between what the client wants and what senior management wants. At the end of each day, the project manager must ensure that both sides are happy with the project's performance. Because the planning gap for clinical projects is persistent and widespread, managing each section of a typical project plan during the definition and planning stages is key to the success of the study.[23],[24],[25]


  Conclusion Top


As the need to meet deadlines becomes more important, producing good and stable project plans become imperative. We can see that the critical path method or CPA is very useful for determining activities that can lead to project delay. Based on actual results, resource reallocation can be considered for further better management of complex CTs. The management of CT resources can only be carried out effectively if a series of accurate resource models can be produced that can provide a range of project execution alternatives. In this way, the project may be effectively monitored, and realistic schedules can be maintained.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Richardson B, Newman RW. Clinical Trial Management – An Integrated Process a Report. Available from: http://www. touchbriefings.com. [Last accessed on 2014 Aug 23].  Back to cited text no. 1
    
2.
Califf RM. Clinical trials bureaucracy: Unintended consequences of well-intentioned policy. Clin Trials 2006;3:496-502.  Back to cited text no. 2
    
3.
Farrell B, Kenyon S, Shakur H. Managing clinical trials. Trials 2010 13;11:78.  Back to cited text no. 3
    
4.
Bruce LM. Measurements for Sponsors, Contract Research Organizations, and Site Management Organization. DIA 34th Annual Meeting, Thinking Globally: Product Development, Registration and Marketing in the New Millennium, 7-11 June, Boston, Massachusetts; 1998.  Back to cited text no. 4
    
5.
Halloran L. Clinical study project plans. J Clin Res Best Pract 2010;6:9.  Back to cited text no. 5
    
6.
DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003;22:151-85.  Back to cited text no. 6
    
7.
Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008;59:1-12.  Back to cited text no. 7
    
8.
Jones TC. How can clinical research and regulatory processes meet the challenge of rapid drug discovery? Curr Drug Discov J 2001. Available from: http://www.currentdrugdicsovery.com. [Last accessed on 2014 Aug 24].  Back to cited text no. 8
    
9.
Back WE, Moreau KA. Information management strategies for project management. Proj Manage J 2001;32:10-20.  Back to cited text no. 9
    
10.
Biotech 2005: Life Sciences: A Move Towards Predictability. Burrril and Company, 2005.  Back to cited text no. 10
    
11.
Kim M. What is the Role of the Project Manager in a Contract Research Organization? Global Project Management Inc. Research SoCRA SOURCE, November, 2003. p. 22.  Back to cited text no. 11
    
12.
Miller JA. Concept Extract from Implementing Activity-Based Management in Daily Operations. New Jersey: John Wiley and Sons, Inc., 1996. p. 36-41.  Back to cited text no. 12
    
13.
Archibald RD, Villoria RL. Network-based Management Systems. New York: Wiley; 1966.  Back to cited text no. 13
    
14.
Critical Chain Ltd., Critical Chain vs. Critical Path; 2003a. Available from: http://www.criticalchain.co.uk/How/ CriticalChainvsCriticalPa.html. [Last accessed on 2013 Apr 29].  Back to cited text no. 14
    
15.
Carlson DA, Young SM. Activity -based total quality management at American express. J Cost Manage Spring 1993; p. 52-5.  Back to cited text no. 15
    
16.
Critical Chain Ltd., Key characteristics of Critical Chain Project Management; 2003b. Available from: http://www.criticalchain. co.uk/How/KeyPoints.html. [Last accessed on 2013 Apr 29].  Back to cited text no. 16
    
17.
Yusuf S. Randomized clinical trials: Slow death by a thousand unnecessary policies? CMAJ 2004;171:889-92.  Back to cited text no. 17
    
18.
Moses H 3rd, Dorsey ER, Matheson DH, Thier SO. Financial anatomy of biomedical research. JAMA 2005;294:1333-42.  Back to cited text no. 18
    
19.
Herroelen W, Leus R. Critical chain project scheduling: Do not oversimplify Proj Manage J 2002;33:48-60.  Back to cited text no. 19
    
20.
Haughey D. Avoiding the Project Management Obstacle Course. Available from: http://www.projectsmart.co.uk/docs/project_ management_obstacle_course.pdf. [Last accessed on 2014 Aug 22].  Back to cited text no. 20
    
21.
Young C, Godlee F. Managing suspected research misconduct. BMJ 2007;334:378-9.  Back to cited text no. 21
    
22.
Seale JP, Gebski VJ, Keech AC. Generalising the results of trials to clinical practice. Med J Aust 2004;181:558-60.  Back to cited text no. 22
    
23.
Fletcher, Smith DB. Managing for value: Developing a performance measurement system integrating economic value added and the balanced scorecard in strategic planning. J Bus Strateg 2004;21:1-16.  Back to cited text no. 23
    
24.
Globerson S. The impact of the project manager on project management planning processes. Proj Manage J 2002;33:58-65.  Back to cited text no. 24
    
25.
Herroelen W, Leus R. On the merits and pitfalls of critical chain scheduling J Oper Manage 2001;19:559.  Back to cited text no. 25
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]
 
 
    Tables

  [Table 1], [Table 2]


This article has been cited by
1 A hybrid type I randomized effectiveness-implementation trial of patient navigation to improve access to services for children with autism spectrum disorder
Sarabeth Broder-Fingert,Morgan Walls,Marilyn Augustyn,Rinad Beidas,David Mandell,Shannon Wiltsey-Stirman,Michael Silverstein,Emily Feinberg
BMC Psychiatry. 2018; 18(1)
[Pubmed] | [DOI]
2 Need for Outcome Scenario Analysis of Clinical Trials in Diabetes
Rosa Garcia-Verdugo,Michael Erbach,Oliver Schnell
Journal of Diabetes Science and Technology. 2017; 11(2): 327
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   Abstract
  Introduction
   Rational Methodo...
  Discussion
  Conclusion
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed4595    
    Printed54    
    Emailed0    
    PDF Downloaded460    
    Comments [Add]    
    Cited by others 2    

Recommend this journal